thalidomide has been researched along with Thyroid Diseases in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Thyroid Diseases: Pathological processes involving the THYROID GLAND.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Central hypothyroidism is a well-recognized side effect of bexarotene." | 4.89 | Thyroid dysfunction as an unintended side effect of anticancer drugs. ( Appetecchia, M; Baldelli, R; Barnabei, A; Corsello, SM; Paragliola, R; Torino, F, 2013) |
| "Lenalidomide is an antiangiogenic drug associated with hypothyroidism." | 1.37 | Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review. ( Brown, K; Clayton, W; Figaro, MK; Jagasia, S; Kassim, A; Lakhani, VT; Usoh, C, 2011) |
| "Goiter is relatively common in infants whose mothers were treated with propylthiouracil and other antithyroid drugs, yet they usually show normal thyroid function." | 1.25 | Human experiences related to adverse drug reactions to the fetus or neonate from some maternally administered drugs. ( Shirkey, HC, 1972) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Torino, F | 1 |
| Barnabei, A | 1 |
| Paragliola, R | 1 |
| Baldelli, R | 1 |
| Appetecchia, M | 1 |
| Corsello, SM | 1 |
| Figaro, MK | 1 |
| Clayton, W | 1 |
| Usoh, C | 1 |
| Brown, K | 1 |
| Kassim, A | 1 |
| Lakhani, VT | 1 |
| Jagasia, S | 1 |
| Shirkey, HC | 1 |
1 review available for thalidomide and Thyroid Diseases
| Article | Year |
|---|---|
Thyroid dysfunction as an unintended side effect of anticancer drugs.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2013 |
2 other studies available for thalidomide and Thyroid Diseases
| Article | Year |
|---|---|
Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Incidence; Le | 2011 |
Human experiences related to adverse drug reactions to the fetus or neonate from some maternally administered drugs.
Topics: Abnormalities, Drug-Induced; Antineoplastic Agents; Antithyroid Agents; Contraceptives, Oral; Diethy | 1972 |